The Medical and Health Bureau of the Hong Kong Special Administrative Region Government announced on the 22nd that the Guangdong Hong Kong Macao Greater Bay Area International Clinical Trial Institute, established and wholly owned by the government, has officially launched the "Guangdong Hong Kong Macao Greater Bay Area Clinical Trial Collaboration Platform".

It is reported that the "Guangdong Hong Kong Macao Greater Bay Area Clinical Trial Collaboration Platform" is a unified service portal jointly established by "one institution, one center", aiming to integrate clinical trial resources in the Greater Bay Area, provide a one-stop service entrance for global biopharmaceutical enterprises, research and development institutions, and researchers, and focus on rare disease drugs, high-end tumor drugs, as well as advanced therapeutic products such as cell and gene therapies.

On that day, the Guangdong Hong Kong Macao Greater Bay Area International Clinical Trial Institute officially established the "Real World Research and Application Center". It is reported that the center will enhance the access and application of health and medical databases, and integrate real-world data generated under the "Hong Kong Macau Medical Device Connect" policy to support registration applications for innovative medical devices in Hong Kong, mainland China, and overseas, accelerating product research and development, approval, and market launch. As of December 10th this year, the designated mainland medical institutions (a total of 71) under the "Hong Kong Macau Medical Device Connect" have introduced a total of 140 types of drugs and medical devices that have been listed in Hong Kong and Macau, including 63 types of drugs and 77 types of medical devices, benefiting over 17000 people.

On September 9th of this year, the Guangdong Hong Kong Macao Greater Bay Area International Clinical Trial Institute signed a memorandum of cooperation with the Li Ka shing School of Medicine of the University of Hong Kong and the international biopharmaceutical company GlaxoSmithKline, launching the institute's first real-world data research project.

It is reported that the experimental institute will better integrate the complete biopharmaceutical technology research and development and technology industry chain in the Greater Bay Area, make good use of the special policies of the country to benefit Hong Kong, fully leverage Hong Kong's "super contact" role of "relying on the motherland and connecting the world", promote Hetao to become a window for the transformation of innovative biopharmaceutical achievements "imported and exported", accelerate the access of patients in the Greater Bay Area to advanced diagnosis and treatment, and develop new quality productivity.